Cargando…

SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma

Renal cell carcinoma is highly inflamed, and tumor cells are embedded into a microenvironment enriched with IL1. While inflammatory pathways are well characterized in the immune system, less is known about these same pathways in epithelial cells; it is unclear if and how innate immune signals direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantione, Maria Elena, Sana, Ilenia, Vilia, Maria Giovanna, Riba, Michela, Doglioni, Claudio, Larcher, Alessandro, Capitanio, Umberto, Muzio, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256934/
https://www.ncbi.nlm.nih.gov/pubmed/35814450
http://dx.doi.org/10.3389/fonc.2022.894413
_version_ 1784741222535921664
author Mantione, Maria Elena
Sana, Ilenia
Vilia, Maria Giovanna
Riba, Michela
Doglioni, Claudio
Larcher, Alessandro
Capitanio, Umberto
Muzio, Marta
author_facet Mantione, Maria Elena
Sana, Ilenia
Vilia, Maria Giovanna
Riba, Michela
Doglioni, Claudio
Larcher, Alessandro
Capitanio, Umberto
Muzio, Marta
author_sort Mantione, Maria Elena
collection PubMed
description Renal cell carcinoma is highly inflamed, and tumor cells are embedded into a microenvironment enriched with IL1. While inflammatory pathways are well characterized in the immune system, less is known about these same pathways in epithelial cells; it is unclear if and how innate immune signals directly impact on cancer cells, and if we could we manipulate these for therapeutic purposes. To address these questions, we first focused on the inflammatory receptors belonging to the IL1- and Toll-like receptor family including negative regulators in a small cohort of 12 clear cell RCC (ccRCC) patients’ samples as compared to their coupled adjacent normal tissues. Our data demonstrated that renal epithelial cancer cells showed a specific and distinctive pattern of inflammatory receptor expression marked by a consistent downregulation of the inhibitory receptor SIGIRR mRNA. This repression was confirmed at the protein level in both cancer cell lines and primary tissues. When we analyzed in silico data of different kidney cancer histotypes, we identified the clear cell subtype as the one where SIGIRR was mostly downregulated; nonetheless, papillary and chromophobe tumor types also showed low levels as compared to their normal counterpart. RNA-sequencing analysis demonstrated that IL1 stimulation of the ccRCC cell line A498 triggered an intrinsic signature of inflammatory pathway activation characterized by the induction of distinct “pro-tumor” genes including several chemokines, the autocrine growth factor IL6, the atypical co-transcription factor NFKBIZ, and the checkpoint inhibitor PD-L1. When we looked for the macroareas most represented among the differentially expressed genes, additional clusters emerged including pathways involved in cell differentiation, angiogenesis, and wound healing. To note, SIGIRR overexpression in A498 cells dampened IL1 signaling as assessed by a reduced induction of NFKBIZ. Our results suggest that SIGIRR downregulation unleashes IL1 signaling intrinsic to tumor cells and that manipulating this pathway may be beneficial in ccRCC.
format Online
Article
Text
id pubmed-9256934
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92569342022-07-07 SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma Mantione, Maria Elena Sana, Ilenia Vilia, Maria Giovanna Riba, Michela Doglioni, Claudio Larcher, Alessandro Capitanio, Umberto Muzio, Marta Front Oncol Oncology Renal cell carcinoma is highly inflamed, and tumor cells are embedded into a microenvironment enriched with IL1. While inflammatory pathways are well characterized in the immune system, less is known about these same pathways in epithelial cells; it is unclear if and how innate immune signals directly impact on cancer cells, and if we could we manipulate these for therapeutic purposes. To address these questions, we first focused on the inflammatory receptors belonging to the IL1- and Toll-like receptor family including negative regulators in a small cohort of 12 clear cell RCC (ccRCC) patients’ samples as compared to their coupled adjacent normal tissues. Our data demonstrated that renal epithelial cancer cells showed a specific and distinctive pattern of inflammatory receptor expression marked by a consistent downregulation of the inhibitory receptor SIGIRR mRNA. This repression was confirmed at the protein level in both cancer cell lines and primary tissues. When we analyzed in silico data of different kidney cancer histotypes, we identified the clear cell subtype as the one where SIGIRR was mostly downregulated; nonetheless, papillary and chromophobe tumor types also showed low levels as compared to their normal counterpart. RNA-sequencing analysis demonstrated that IL1 stimulation of the ccRCC cell line A498 triggered an intrinsic signature of inflammatory pathway activation characterized by the induction of distinct “pro-tumor” genes including several chemokines, the autocrine growth factor IL6, the atypical co-transcription factor NFKBIZ, and the checkpoint inhibitor PD-L1. When we looked for the macroareas most represented among the differentially expressed genes, additional clusters emerged including pathways involved in cell differentiation, angiogenesis, and wound healing. To note, SIGIRR overexpression in A498 cells dampened IL1 signaling as assessed by a reduced induction of NFKBIZ. Our results suggest that SIGIRR downregulation unleashes IL1 signaling intrinsic to tumor cells and that manipulating this pathway may be beneficial in ccRCC. Frontiers Media S.A. 2022-06-22 /pmc/articles/PMC9256934/ /pubmed/35814450 http://dx.doi.org/10.3389/fonc.2022.894413 Text en Copyright © 2022 Mantione, Sana, Vilia, Riba, Doglioni, Larcher, Capitanio and Muzio https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mantione, Maria Elena
Sana, Ilenia
Vilia, Maria Giovanna
Riba, Michela
Doglioni, Claudio
Larcher, Alessandro
Capitanio, Umberto
Muzio, Marta
SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
title SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
title_full SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
title_fullStr SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
title_full_unstemmed SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
title_short SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
title_sort sigirr downregulation and interleukin-1 signaling intrinsic to renal cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256934/
https://www.ncbi.nlm.nih.gov/pubmed/35814450
http://dx.doi.org/10.3389/fonc.2022.894413
work_keys_str_mv AT mantionemariaelena sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT sanailenia sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT viliamariagiovanna sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT ribamichela sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT doglioniclaudio sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT larcheralessandro sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT capitanioumberto sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma
AT muziomarta sigirrdownregulationandinterleukin1signalingintrinsictorenalcellcarcinoma